🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.7290
-0.0400 (-5.20%)
Nov 20, 2026, 5:29 PM CET

IRLAB Therapeutics AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
67.4257.4694.635.6861.14207.78
Other Revenue
4.37-----
71.7957.4694.635.6861.14207.78
Revenue Growth
-16.09%-39.28%1566.57%-90.71%-70.58%69160.67%
Cost of Revenue
64.1199.38136.29128.41125.9181.74
Gross Profit
7.68-41.91-41.66-122.73-64.77126.05
Selling, General & Admin
42.9146.1246.1853.0842.4831.02
Other Operating Expenses
-4.95-5.33-19.46-0.04-0.0338.97
Operating Expenses
42.0945.1131.3157.3647.2373.47
Operating Income
-34.4-87.02-72.97-180.09-11252.58
Interest Expense
-7.28-17.99-10.48-0.2-0.3-0.37
Interest & Investment Income
0.421.382.463.13-0
Currency Exchange Gain (Loss)
-6.38-6.38-2.14-0.68-1.11-0.43
Other Non Operating Income (Expenses)
0.88-0-0--
EBT Excluding Unusual Items
-46.76-110.01-83.13-177.84-113.4151.78
Pretax Income
-46.76-110.01-83.13-177.84-113.4151.78
Earnings From Continuing Operations
-46.76-110.01-83.13-177.84-113.4151.78
Net Income
-46.76-110.01-83.13-177.84-113.4151.78
Net Income to Common
-46.76-110.01-83.13-177.84-113.4151.78
Net Income Growth
------
Shares Outstanding (Basic)
1006752525252
Shares Outstanding (Diluted)
1006752525252
Shares Change
70.02%29.17%-0.07%0.16%8.54%
EPS (Basic)
-0.47-1.64-1.60-3.43-2.191.00
EPS (Diluted)
-0.47-1.64-1.60-3.43-2.191.00
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-83.24-55.22-65.79-165.14-145.49127.93
Free Cash Flow Per Share
-0.83-0.82-1.27-3.18-2.812.47
Gross Margin
10.70%-72.94%-44.03%--105.94%60.66%
Operating Margin
-47.92%-151.44%-77.11%-3171.72%-183.20%25.30%
Profit Margin
-65.13%-191.45%-87.85%-3132.07%-185.50%24.92%
Free Cash Flow Margin
-115.95%-96.10%-69.52%-2908.47%-237.97%61.57%
EBITDA
-33.75-86.17-72.08-179.17-111.2753.07
EBITDA Margin
-47.02%-149.97%-76.17%--182.00%25.54%
D&A For EBITDA
0.650.850.890.920.740.49
EBIT
-34.4-87.02-72.97-180.09-11252.58
EBIT Margin
-47.92%-151.44%-77.11%--183.20%25.30%
Revenue as Reported
71.662.8114.085.7261.28207.91